Sector News

Sun Pharma enhances presence in Russia

November 23, 2016
Life sciences

Indian drugmaker Sun Pharma along with its subsidiaries and/or associate companies, have executed a definitive agreement to take a majority stake in a Russian company in order to expand its presence in that market.

As a result, Sun Pharma will acquire an 85.1% stake in JSC Biosintez, which is engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. The equity consideration for the 85.1% stake is $24 million.

Sun Pharma would also assume a debt of about $36 million as part of this transaction. Biosintez is a Russian pharmaceutical company focusing on the hospital segment with annual revenues of around $52 million for 2015. It has a manufacturing facility in Penza region with capabilities to manufacture a wide variety of dosage forms including pharmaceuticals for injections, blood substitutes, blood preservatives, ampoules, tablets, ointment, creams, gels, suppositories, APIs, etc.

According to Aalok Shanghvi, head of emerging markets, Sun Pharma:“This acquisition is consistent withSun Pharma’s philosophy to invest in strategic Emerging Markets. This transaction gives us access to localmanufacturing capability across multiple dosage forms in Russia, enabling us to serve the Russia pharmaceuticalmarket more effectively.”

“This is an important milestone for us,” added Artur Valliev, country head at Sun Pharma Russia, saying: “The acquisition signifies Sun Pharma’s commitment to Russia and the Russian 2020 plan for localization.”

The transaction, expected to be completed by end of 2016, is subject to approval of the Russian Federal Anti-Monopoly Service and other closing conditions.

As per IMS (MAT September 2016), the Russian pharmaceutical market recorded sales of approximately $10 billion. The market recorded a growth of 7.4% in local currency terms.

Source: The Pharma Letter

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.